Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective.
Sign Up to like & getrecommendations! Published in 2022 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2022.2112664
Abstract: INTRODUCTION For many of the 537 million adults living now with diabetes, the cost of insulin is becoming prohibitive as the insulin prices have tripled between 2002-2013. Globally, the direct annual cost of healthcare expenditure… read more here.
Keywords: facts every; interchangeable biosimilars; biosimilars facts; biosimilar insulin ... See more keywords
Biosimilar insulin concepts
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Diabetes"
DOI: 10.1111/1753-0407.13267
Abstract: Insulin use has dramatically increased over the past 30 years, in part because of the increasing realization of its role in the treatment of type 2 diabetes (T2D) (Figure 1A). Worldwide, the prevalence of type… read more here.
Keywords: insulin analogs; biosimilar insulin; insulin; reference product ... See more keywords
Introduction of biosimilar insulins in Europe
Sign Up to like & getrecommendations! Published in 2017 at "Diabetic Medicine"
DOI: 10.1111/dme.13400
Abstract: Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar®), in 2014 expanded the treatment options available to people with diabetes. As biosimilar insulin products come to market, it is important to… read more here.
Keywords: insulin; insulins europe; insulin glargine; biosimilar insulin ... See more keywords
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.1111/dom.14994
Abstract: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and US‐licensed Humulin® N (Humulin‐N; Eli Lilly and Company, Indianapolis, IN, USA) in healthy… read more here.
Keywords: pharmacodynamic equivalence; biosimilar insulin; equivalence; pharmacokinetic pharmacodynamic ... See more keywords
Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine
Sign Up to like & getrecommendations! Published in 2021 at "PLoS ONE"
DOI: 10.1371/journal.pone.0253168
Abstract: Insulin glargine is a long-acting analogue of human insulin that has been used to manage hyperglycemia in patients with diabetes mellitus (DM) for nearly 20 years. Insulin glargine has a relatively constant concentration-time profile that… read more here.
Keywords: biosimilar insulin; insulin glargine; proposed biosimilar; myl 1501d ... See more keywords